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Received 23 Nov 2015; first review completed 8 Dec 2015; accepted in final form 22 Dec 2015ABSTRACT—Objective: Reduced ex vivo lipopolysaccharide (LPS) stimulated whole blood pro-inflammatory cytokine
release is a hallmark of immunosuppression in the critically ill and predicts adverse clinical outcomes. No standard technique
for performing the assay currently exists. The impact of methodological heterogeneity was determined. Design, Setting,
Subjects, and Interventions: Clinical experimental study set in a research laboratory. Venous blood from 5 to 10 healthy
volunteers/experiment (total participant group: 18 subjects, 72% men, mean age 32) was stimulated ex vivo to evaluate the
effect of variables identified via literature review on tumor necrosis factor-a (TNFa) release. These included sample
handling, stimulation technique, and incubation conditions. Reporting convention was additionally assessed. Main
Results: Measured TNFa release was significantly altered by source of LPS, concentration of LPS employed, duration
and temperature of incubation prior to supernatant aspiration, and predilution of blood (repeated measures ANOVA, all
P<0.01). Sample handling prior to stimulation (anticoagulant employed, time to LPS addition, and storage temperature)
also caused significant alterations in TNFa release. Considerable interindividual variation was observed (range 1,024–4,649
pg/mL, mean 2,339 pg/mL). Normalization by monocyte count and pretreatment with a cyclooxygenase inhibitor (indo-
methacin 10mM) reduced the coefficient of variation from 47.17% to 32.09%. Conclusions: Inconsistency in interlabor-
atory methodology and reporting impairs interpretation, comparability, and reproducibility of the ex vivo LPS-stimulated
whole blood cytokine release assay. A standardized validated technique is required. The advent of trials of immunoadjuvant
agents renders this a clinical imperative.
KEYWORDS—Diagnostic, endotoxin tolerance, immunoadjuvant, lipopolysaccharide, sepsis, stratified medicine,
therapeutics, tumor necrosis factor aINTRODUCTION
Late mortality in critically ill patients with severe sepsis, or
following trauma, burn or major surgery, is now thought due to
the predominance of anti-inflammatory processes. Whether
excessive, sustained, or secondary to a failure of the immune
system to recover from their functional consequences, the net
effect is one of immunosuppression characterized by suscepti-
bility to opportunistic infection and acquisition of secondary
sepsis (1,2). Therapeutically, this may be addressed via aug-
mentation of the immune system with immunoadjuvant agents
(3), an approach that has demonstrated initial promise in
selected septic patients (4,5).Copyright © 2016 by the Shock Society. Unauthor
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490The key to an immunorestorative strategy is patient stratifi-
cation—identifying individuals with clinically meaningful
immunosuppression who may benefit from treatment. To date,
two interrelated biomarkers have repeatedly proven predictive of
acquisition of both nosocomial infection and mortality and have
consequently been used to guide inclusion in clinical trials:
monocyte human leukocyte antigenDR (mHLA-DR) expression
(6,7) and ex vivo lipopolysaccharide (LPS)-stimulated whole
blood (WB) tumor necrosis factor a (TNFa) release (8–10).
While a standardized methodology and reporting tradition has
been established for mHLA-DR (11), the same is not true for ex
vivo cytokine release, potentially leading to disparities in case
definition, identification, treatment allocation, and outcome
determination that impair data interpretation and comparability.
This study sought to identify key inter-laboratory differences
in sample handling, technical performance of the WB ex vivo
cytokine release assay, and result reporting convention, deter-
mining their impact on measured TNFa and hence quantifi-
cation of immune competence.MATERIALS AND METHOD
Study design, setting, and subjects
Eighteen healthy volunteers (13 men [72.2%], mean age 32 years) were
recruited, 5 to 10 individuals participating in each experiment dependent on the
variable evaluated. All samples were obtained and processed in a clinical
research laboratory. Ethical approval for the protocol was provided by the
University College London Research Ethics Committee (project ID: 4332/001).ized reproduction of this article is prohibited.
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Health Volunteer Blood: Venous blood was collected and stored in lithium
heparin (LH, Grenier Bio-One Vacuette), ethylenediaminetetraacetic acid
(EDTA), or sodium citrate (Na Cit, both BDBiosciences Vacutainer) containing
tubes prior to stimulation.
Stimulation: Unless otherwise stated 1mL heparinized WB was diluted 1:5
in RPMI (Gibco, Grand Island, NY) in 15mL polypropylene tubes (Fisher
Scientific, Grand Island, NY) and stimulated for 6 h (378C, 250 rpm) with 1 ng/
mL LPS (Salmonella abortus equi S-form [TLRgrade], Enzo Life Sciences,
Farmingdale, NY), after Kox et al. (12). Blood was stimulated within 30 min of
draw. After incubation samples were centrifuged at 2000 g for 10 min at 208C
and supernatant stored at 808C. Three technical repeats (tubes/individual/
condition or time-point) were performed.
Variables: On the basis of the results of the literature review the core
technique was modified to evaluate the effect of LPS type (Escherichia coli
0111:B4 and 055:B5 [Sigma-Aldrich, St. Louis, Mo], Salmonella abortus equi,
Salmonella Minnesota R-form serotype: R595 [Hycult]), LPS concentration (1
pg/mL to 100 ng/mL Salmonella abortus equi), duration of stimulation (30min,
1, 2, 4, 6, 8, 24 h), anticoagulant employed (LH, EDTA, Na Cit), incubation
conditions (temperature [208C vs. 378C], agitation [0 rpm vs. 250 rpm]), sample
dilution (none, 1:1, 1:5, 1:10), and sample handling (time to stimulation [2, 4, 6,
12 h], storage temperature [48C, 208C, 378C]). In addition, the effect of
pretreating the blood with a non-steroidal anti-inflammatory drug (indometha-
cin 10mM [Sigma-Aldrich], a dual cyclooxygenase 1 and 2 inhibitor) was
evaluated. Where not supplied in solution LPS was reconstituted in sterile
deionized water and vortexed extensively prior to use.
TNFa and Monocyte Quantification: The concentration of TNFa was
determined via enzyme-linked immunosorbent assay according to the manu-
facturer’s instructions (Duoset, R&D systems, Minneapolis, MN). Differential
leucocyte counts were performed via a Sysmex XE2100 flow cytometric
analyzer by The Doctors Laboratory (London, UK).
Statistical analysis
Data points represent the average of three technical repeats, each assayed in
duplicate. The D’Agostino–Pearson test was used to test for normality.
Differences between categorical variables were tested for using either repeated
measures one-way or two-way analysis of variance (RM-ANOVA, incorporat-
ing the Greenhouse–Geisser correction) with Tukey multiple comparisons test,
or paired t tests. Statistical significance was set at P< 0.05. All analyses were
conducted in Prism 6 (GraphPad Software).RESULTS
Stimulation with LPS (1 ng/mL) from different bacterial
sources elicited significantly different concentrations of TNFa
(P< 0.001, one-way RM-ANOVA, Fig. 1A), with ‘‘rough’’-LPS
derived from S. minnesota causing significantly greater TNFa
release than the 3 ‘‘smooth’’-LPS sources (all P< 0.01, Tukey).
Cytokine release was further altered by the use of alternate
anticoagulants (P< 0.001, one-wayRM-ANOVA) being signifi-
cantly lowerwhenEDTAwas employed than either LH orNaCit
(both P< 0.01, Tukey, Fig. 1C). While incubation of stimulated
WB at 378Cwas necessary—samples at 208C releasing minimal
TNFa (mean 89.27 pg/mL, Fig. 1E)—no significant difference
was observed between agitated (mean 4,049 pg/mL, SD 1653)
and nonagitated samples (4,459 pg/mL, SD 1967; P¼ 0.15,
paired t test). Stimulation with either increasing doses of LPS
(S. abortus equi), or for variable periods of time, predictably led
to differential concentrations of TNFa in the supernatant when
aspirated; 1 ng/mL and incubation time>4 h leading tomaximal
or equivalent responses (Fig. 1B andD). Spontaneous production
of TNFa in un-stimulated blood was not observed.
Variations in sample handling prior to LPS stimulation caused
discrepancies in assayed TNFa. Both time to LPS addition and
storage temperature significantly effected supernatant TNFa
concentration (both P< 0.001, 2-way RM ANOVA), increasing
time leading to lower release and 208-C storage elicitingCopyright © 2016 by the Shock Society. Unauthorizesignificantly greater release than either 48C or 378C (both P
< 0.001, Tukey). No significant interaction was observed
between the two variables (P¼ 0.2). Predilution of blood, for
ease of technical performance and to enhance supernatant yield,
as expected, leads to a fall in TNFa concentration per unit
supernatant with an increased ratio of media to WB (Fig. 2A).
This decrease was however not directly proportional, normal-
ization by dilution factor failing to create equivalence between
technical approaches (P< 0.01, one-way RM-ANOVA).
Considerable interindividual variation in LPS-stimulated
TNFa release was observed, the supernatant of heparinized
blood from 10 volunteers stimulated with 1 ng/mL S. abortus
equi (6 h, 1:5 dilution, 378C, agitated) having measured con-
centrations ranging from 1,024 to 4,649 pg/mL (mean 2,339 pg/
mL, Fig. 2B). Expression of assayed TNFa as a function of cell
number (pg/mL per 1,000monocytes) rather than as an absolute
concentration in supernatant (pg/mL) resulted in a decrease in
the co-efficient of variation (39.95% vs. 47.17% respectively,
Fig. 2B). The addition of a cyclooxygenase inhibitor to the
assay both decreased the co-efficient of variation (37.67% vs.
47.17%) and significantly increased the measured TNFa con-
centration (panel A, Supplemental Figure 1, Supplemental
Digital Content 1, at http://links.lww.com/SHK/A358; LPS
alone mean 2339 pg/mL, NSAID LPS 3108 pg/mL,
P< 0.001, RM t test). Normalization of these values by mono-
cyte count further reduced the co-efficient of variation
(32.09%, Panel B, Supplemental Figure 1, Supplemental
Digital Content 1, at http://links.lww.com/SHK/A358). While
intra-individual variation in serially assessed TNFa release was
additionally noted, the statistical significance of this was not
tested (panel C, Supplemental Figure 1, Supplemental Digital
Content 1, at http://links.lww.com/SHK/A358).DISCUSSION
Ex vivo LPS-stimulated WB TNFa release is a biomarker of
monocyte function and reflective of global immune compe-
tence, persistent reduction being predictive of adverse out-
comes, and its restoration an indicator of clinical
improvement (4,9,10,13). However, to date, laboratories have
employed divergent techniques to determine and report this key
metric (see Table 1) (14–18), impairing interpretation, com-
parability, and reproducibility. No clear rationale underlies
these alternate approaches.
Selection of LPS source, LPS concentration, duration and
temperature of incubation, anticoagulant and decision to dilute
the blood varied extensively between laboratories, and were all
demonstrated to significantly alter the assay result. Sample
handling prior to stimulation, rarely reported in manuscripts,
was additionally observed to contribute variance—both time to
LPS addition and WB storage temperature— impacting sub-
sequent TNFa release. Reporting inconsistencies further obfus-
cate results, studies presenting either concentration of TNFa
alone (4) or expressing this as a factor of cell number (total
WBC count (19), monocyte count (12)), and failing to describe
the number of biological and/or technical repeats undertaken
per time-point/condition per individual. Both normalizing
TNFa concentration to monocyte count and pretreatment ofd reproduction of this article is prohibited.
FIG. 1. Effect of discrete variables on the ex vivo lipopolysaccharide (LPS)-stimulated whole blood (WB) cytokine release assay.WB (1mL) from
healthy volunteers was stimulated in triplicate with (A) LPS (1 ng/mL) from four different bacterial sources (Escherichia coli 0111:B4 and 055:B5, Salmonella
abortus equi S-form [SAE], Salmonella Minnesota R-form serotype: R595). TNFa from un-stimulated cells was undetectable. B, n¼9. Different concentrations of
LPS (SAE, 10 pg/mL to 100 ng/mL). C, n¼10. Alternate anticoagulants: lithium heparin, sodium citrate or EDTA (all SAE, 1 ng/mL). D, n¼5. For different lengths
of time prior to supernatant removal (SAE, 1 ng/mL, 30 min to 24h). E, n¼5. In alternate incubation conditions either 208C or 378C, with (þ) or without ()
agitation. F, n¼10. Variations in sample handling (time to stimulation [2, 4, 6, 12h] and storage temperature [48C, 208C, 378C]). n¼5 per condition. Lines denote
mean and 95% confidence intervals. Differences between categorical variables were tested for using either repeated measures one-way or two-way analysis of
variance with Tukey multiple comparisons test, or paired t tests. Statistical significance is indicated as * P<0.05, ** P<0.01, *** P<0.001. EDTA indicates
ethylenediaminetetraacetic acid; ns, non-significant; TNFa, tumor necrosis factor a.
492 SHOCK VOL. 45, No. 5 SEGRE AND FULLERTONthe blood with a cyclooxygenase inhibitor were found to
synergistically reduce the coefficient of variation; however,
the functional and diagnostic relevance of this is unclear.
These results are not unexpected. It has long been known that
varying the LPS dose or duration of incubation alters the
readout of the ex vivo WB assay (14,15). Nor is it surprising
that sample handling, different sources of LPS, dilution of the
blood, or choice of anticoagulant alters measured TNFa con-
centrations. What is remarkable however is the lack of deri-
vation and adoption of a uniform method and reporting
standard for this important test of immune dysfunction: a
deficiency that needs to be addressed. Stratified immunoadju-
vant therapy holds great promise for critically ill patientsCopyright © 2016 by the Shock Society. Unauthor(3,20). Establishing a panel of biomarkers with associated
clinically relevant definitions and predictive value, to deter-
mine who to treat, when to treat them, and what to administer
will be critical to its success (21). It is vital that avoidable
methodological heterogeneity does not confound inclusion
criteria, determination of outcome, and thus the external
validity of future clinical trials.
It should be noted that this study was not designed to define a
‘‘gold-standard’’ method of undertaking the ex vivoWB stimu-
lation assay, instead seeking to identify key sources of meth-
odological variance and highlight their implications.
Participants were healthy volunteers, a ‘‘core’’ method was
selected and only one method of TNFa measurement wasized reproduction of this article is prohibited.
FIG. 2. Variations in reporting convention of data from the ex vivo LPS-stimulated WB cytokine release assay. A, Left panel—WB (1mL) was
stimulated (SAE, 1 ng/mL) either un-diluted or prediluted with RPMI at a 1:1, 1:5, or 1:10 ratio. n¼10 per condition. Right panel—measured concentrations were
normalized by dilution factor to examine for equivalence. Lines denote mean and 95% confidence intervals. Differences were tested for using repeated measures
one-way analysis of variance with Tukey multiple comparisons test. Statistical significance is indicated as * P<0.05, ** P <0.01. B, TNFa expressed as either an
absolute concentration in aspirated supernatant or as a factor of cell number (/1000monocytes). n¼10. TNFa indicates tumor necrosis factor a; WB, whole blood.
SHOCK MAY 2016 STANDARDIZING BIOMARKERS OF IMMUNOSUPPRESSION 493performed. Response variation may have differed had an
alternate system and population been employed. In particular,
the importance of normalizing TNFa release to monocyte
count—more variable in acute illness—to accurately gauge
immune competence may have been underestimated. The blood
collection tubes employed were sterile and from one batch, yet
not guaranteed to be pyrogen free. Additional technical factorsCopyright © 2016 by the Shock Society. Unauthorize
TABLE 1. Heterogeneity in methodology employed to perform the ex vivo
assa
Ertel
1995 (14)
Ogata
2000 (16)
Wang
2000 (15)
Heagy
2003 (17)
LPS type E. Coli 055:B5 E. Coli 127:B8 E. Coli 026:B7 E. Coli 0111:B
LPS concentration 1 ng to 1mg/mL 10 ng/mL 10 ng/mL 10 ng/mL
Diluent type None Saline None RPMI
Blood /diluent (ratio) 5mL/0 (N/A) NI/5x (1:5) NI/0 (N/A) 1–3mL/0
(N/A)
Incubation/agitation 1–24 h/yes 4 h/NI 2–24 h/yes 3 h/yes
Anticoagulant Heparin Heparin Citrate Heparin
Sample handling
(time/temp.)
NI/NI NI/NI NI/NI NI/NI
TNFa quantification Bioassay NI EIA and bioassay ELISA
Results expression U/mL/1106
monocytes
U/mL pg/mL pg/mL
Indicative results 535.9  75 240  36 1,449–2,484 6,706  715
Eight published papers (first author, year of publication) were selected to exe
(LPS type and concentration, use of diluent and ratio to blood, incubation perio
anticoagulant), sample handling prior to analysis (time and storage temperatu
measurement and reporting of results (absolute TNFa concentration in supern
(SEM or IQR respectively) of TNFa concentrations reported in the control
ELISA indicates enzyme-linked immunosorbent assay; N/A indicates not apnot elaborated here may also impact measured TNFa release
including the method of LPS extraction, purification and
solubilization, and the testing of either fresh or frozen super-
natants. Future work may address these deficiencies and should
seek to formulate and validate the predictive and diagnostic
value of a standardized assay—in conjunction with additional
metrics of immunosuppression—as a clinical imperative.d reproduction of this article is prohibited.
lipopolysaccharide (LPS)-stimulated whole blood cytokine release
y
Ploder
2006 (9)
Allen
2006 (18)
Hall
2011 (10)
Kox
2011 (12)
4 S. Abortus Equi N. Meninigitides S. Abortus Equi E. Coli O55:B5
500 pg/mL 10mg/mL 500 pg/mL 1 ng/mL
RPMI RPMI NI RPMI
50mL/0 (N/A) 500mL/500mL
(1:1)
50mL/500mL
(1:10)
1mL/4mL
(1:5)
4 h/NI 24 h/NI 4 h/NI 24 h/NI
Heparin Heparin Heparin Heparin
NI/Ice NI/NI 1 h/NI NI/NI
Chemi-luminescence NI Chemi-luminescence Luminex Assay
ng/mL pg/mL pg/mL pg/1000 monocytes
1.05–2.8 900  50 900–2,172 55  5
mplify diversity in technical performance of the assay along key variables
d after stimulation [all at 378C], use of agitation during this period, choice of
re from collection to stimulation) method of tumor necrosis factor a (TNFa)
atant or whether normalized to cell number). The range, mean or median
group in each study is also displayed.
plicable; NI, not indicated.
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